A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis

ID Number 09-0007

Principal Investigator(s)
Aaron Miller

Department(s) or Division(s)


The purpose of this study is to find out how effective the study medication, Fingolimod (FTY720) is in delaying disability in patients with Primary Progressive Multiple Sclerosis (PPMS).

Contact Information
Colleen Farrell
(212) 241-3048

Recruiting Patients: No